Terrance G. Johns
Oncogenic Signalling Laboratory and Tumor Targeting Program
Ludwig Institute for Cancer Research
Melbourne Centre
Austin Hospital
Australia
Name/email consistency: high
- The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Johns, T.G., Perera, R.M., Vernes, S.C., Vitali, A.A., Cao, D.X., Cavenee, W.K., Scott, A.M., Furnari, F.B. Clin. Cancer Res. (2007)
- The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. Johns, T.G., Mellman, I., Cartwright, G.A., Ritter, G., Old, L.J., Burgess, A.W., Scott, A.M. FASEB J. (2005)
- Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. Johns, T.G., Adams, T.E., Cochran, J.R., Hall, N.E., Hoyne, P.A., Olsen, M.J., Kim, Y.S., Rothacker, J., Nice, E.C., Walker, F., Ritter, G., Jungbluth, A.A., Old, L.J., Ward, C.W., Burgess, A.W., Wittrup, K.D., Scott, A.M. J. Biol. Chem. (2004)
- Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Johns, T.G., Luwor, R.B., Murone, C., Walker, F., Weinstock, J., Vitali, A.A., Perera, R.M., Jungbluth, A.A., Stockert, E., Old, L.J., Nice, E.C., Burgess, A.W., Scott, A.M. Proc. Natl. Acad. Sci. U.S.A. (2003)
- Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Johns, T.G., Stockert, E., Ritter, G., Jungbluth, A.A., Huang, H.J., Cavenee, W.K., Smyth, F.E., Hall, C.M., Watson, N., Nice, E.C., Gullick, W.J., Old, L.J., Burgess, A.W., Scott, A.M. Int. J. Cancer (2002)
